128940.KS
Hanmi Pharm. Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 460,500.00
−2.85%Year over year
Reported trailing growth
- Revenue
- +12.9%
- EBITDA
- +44.1%
- EBIT
- +40.7%
- EPS
- +118.7%
- Free cash flow
- +134.2%
- Operating cash flow
- +78.4%
Forward estimates
Based on analyst estimates
- Revenue
- +6.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.1%
- EBITDA
- +9.0%
- EBIT
- +12.3%
- Net income
- +27.2%
- EPS
- +27.1%
- Free cash flow
- +4.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026